Firazyr

DRUG2 trials

Sponsors

Shire, Sebastian Videla

Conditions

COVID-19 PneumoniaHereditary Angioedema (HAE)

Phase 2

Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection

CompletedNCT04978051

Sebastian VidelaCOVID-19 Pneumonia

Start: 2021-04-12End: 2022-03-17Updated: 2022-08-03

Unknown Phase

FIRAZYR General Drug Use-Results Survey (Japan)

CompletedNCT04057131

ShireHereditary Angioedema (HAE)

Start: 2018-11-20End: 2024-07-29Updated: 2025-02-21

Related Papers

Real-World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema (HAE): Post-Marketing Surveillance in Japan.

2026-08-21

Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial

Clinical Infectious Diseases2023-01-0413 citations

A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID)

Trials2022-04-126 citations